Track your past therapies so you can answer:

Could ZYNLONTA® (loncastuximab tesirine-lpyl) be my next therapy?

What line of therapy am I at?

If you have been diagnosed with DLBCL and have tried 2 or more therapies, ZYNLONTA® may be right for you. Answer these questions about your treatment history and talk with your doctor about what’s next in your DLBCL treatment plan.

ZYNLONTA® may be an option after most DLBCL therapies. Some adults treated with ZYNLONTA® were able to go on to other therapies afterward.

Please see Important Safety Information below and Full Prescribing Information.

ZYNLONTA® is for people with R/R DLBCL who have tried 2 or more therapies. Please talk to your doctor about the next steps in your treatment plan.

1. For my 1st DLBCL therapy, I tried __________.

2. After the 1st treatment did not work or the cancer came back, I received my 2nd treatment.

I got a transplant (ASCT) along with:

I couldn’t have an ASCT but instead had:

Neither:

3. My 3rd or later therapy was ______________. (select all that apply)

None:

4. After the latest therapy, the cancer came back (relapsed) or the treatment didn’t work (refractory).

ADC Therapeutics respects your privacy and personal information. Please read our Privacy Policy for more information. By interacting with the treatment plan content, you are confirming that you have read, understand, and agree with the Privacy Policy for the information collected on the form above.
Feel free to print your results and share them with your care team.

All other trademarks, registered or unregistered, are the property of their respective owners

ASCT: Autologous stem cell transplant

Anti-CD19: against the B-cell-specific membrane protein CD19 with potential immunostimulating and antineoplastic activities

CD30+: protein found on some T-cells and B-cells (2 types of white blood cells). It is a receptor for a protein called tumor necrosis factor

mAb: monoclonal antibody

Non-GCB: non-germinal center B-cell-type

HDT: High-dose therapy

R-DHAP: Rituximab-dexamethasone-high dose cytarabine (Ara C)-cisplatin (platinum)

R-ESHAP: Rituximab-etoposide-solu-medrone (methylprednisolone)-high dose cytarabine (Ara C)-cisplatin (platinum)

R-GemOx: Rituximab-Gemcitabine-Oxaliplatin

R-GDP: Rituximab-Gemcitabine-Dexamethasone-cisPlatin (carboPlatin)

R-ICE: Rituximab-ifosfamide-carboplatin-etoposide


Please see the full Prescribing Information for ZYNLONTA®, including Patient Information, for additional Important Safety Information.



What is ZYNLONTA®?

Important Safety Information

ZYNLONTA® is a prescription medicine used to treat adults with certain types of large B-cell lymphoma that has come back (relapsed) or that did not respond to previous treatment (refractory), who have already received two or more treatments for their cancer.

It is not known if ZYNLONTA® is safe and effective in children.

The approval of ZYNLONTA® is based on a type of response rate. There is an ongoing study to confirm the clinical benefit of ZYNLONTA®.

Read full Important Safety Information

IMPORTANT SAFETY INFORMATION

What are the possible side effects of ZYNLONTA®?

ZYNLONTA® may cause serious side effects, including:

  • Fluid retention. Your body may hold too much fluid during treatment with ZYNLONTA®. This can be serious. Tell your healthcare provider if you develop new or worsening swelling or puffiness, weight gain, chest pain, shortness of breath, or trouble breathing
  • Low blood cell counts (platelets, red blood cells, and white blood cells). Low blood cell counts are common with ZYNLONTA® but can also be serious or severe. Your healthcare provider will monitor your blood counts during treatment with ZYNLONTA®. Tell your healthcare provider right away if you get a fever of 100.4°F (38°C) or above, or any bruising or bleeding
  • Read full Important Safety Information
  • Infections. Serious infections, including infections that can cause death, have happened in people treated with ZYNLONTA®. Tell your healthcare provider right away if you have new or worsening signs or symptoms of infection
  • Skin reactions. Serious skin reactions have happened in people treated with ZYNLONTA®. Tell your healthcare provider if you get new or worsening skin reactions, including sensitivity to sunlight, skin rash, peeling, redness or irritation. You may burn more easily or get severe sunburns

The most common side effects of ZYNLONTA® include:

  • feeling tired or weak
  • skin rash
  • swelling
  • nausea
  • muscle or joint pain
  • increase in blood sugar (hyperglycemia)
  • changes in certain blood or laboratory tests

ZYNLONTA® may cause fertility problems in males which may affect your ability to father children. Talk to your healthcare provider if this is a concern for you. These are not all of the possible side effects of ZYNLONTA®.

What should I avoid while receiving ZYNLONTA®?

Avoid or limit your exposure to sunlight, including sunlight through glass, such as buildings or vehicle windows and artificial sunlight such as sunlamps or tanning beds. Exposure to sunlight during treatment with ZYNLONTA® can cause skin reaction or rash. Use sun protection measures such as sunscreen and wear loose-fitting clothes that cover your skin while out in sunlight.

Before you receive ZYNLONTA®, tell your healthcare provider about all of your medical conditions, including if you:

  • have an active infection or have had one recently
  • have liver problems
  • are pregnant or plan to become pregnant. ZYNLONTA® can harm your unborn baby

    Females who can become pregnant:

    • your healthcare provider may do a pregnancy test before starting treatment with ZYNLONTA®
    • you should use effective birth control (contraception) during treatment with ZYNLONTA® and for 9 months after the last dose of ZYNLONTA®. Talk to your healthcare provider about effective birth control. Tell your healthcare provider right away if you become pregnant or think that you are pregnant during treatment with ZYNLONTA®

    Males with female partners who can become pregnant:

    • you should use effective birth control (contraception) during treatment with ZYNLONTA® and for 6 months after the last dose of ZYNLONTA®
  • are breastfeeding or plan to breastfeed. It is not known if ZYNLONTA® passes into breast milk. Do not breastfeed during treatment with ZYNLONTA® and for 3 months after the last dose of ZYNLONTA®

Tell your healthcare provider about all the medicines that you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Know the medicines you take. Keep a list of them to show your healthcare provider or pharmacist when you get new medicine.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to ADC Therapeutics at 1-855-690-0340.

Please see the full Prescribing Information for ZYNLONTA®, including Patient Information, for additional Important Safety Information.